Skip to main content

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is an international biopharmaceutical company dedicated to rare diseases. The company organizes its operational reporting and commercial strategy around two key therapeutic areas: Hematology and Immunology. Its product portfolio features biopharmaceuticals for hemophilia care, severe auto-inflammatory syndromes, and specialty metabolic disorders. Revenues are generated through commercial sales of prescription orphan drugs to hospitals, specialty pharmacies, and healthcare systems. The enterprise holds a market-leading European and global position in specialized hematology and niche immunology therapies. Swedish Orphan Biovitrum is headquartered in Stockholm, Sweden, and its shares are traded on Nasdaq Stockholm.

88 of the funds FundTelligence covers report a position in Swedish Orphan Biovitrum.

Legal name
Swedish Orphan Biovitrum AB
Sector
Health Care
Country
Sweden
Funds holding it
88

Funds holding Swedish Orphan Biovitrum

Showing the 8 largest of 88 funds holding it.

Loading...